Q2 2024

Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001477932-24-004869

Q2 2024 · 10-Q

Revenue

$0.00

−100.0% vs Q2 2023

Net Income

-$709.00K

N/M vs Q2 2023

EPS Diluted

-$0.01

N/M vs Q2 2023

Gross Profit$0−100.0%

Operating Income

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	$0.00	$44.00K	$5.00K	$2.00K
Net Income	-$709.00K	-$1.56M	-$926.00K	-$1.03M
EPS Diluted	-$0.01	-$0.03	-$0.04	-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR